Literature DB >> 20606113

Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats.

Giselle C Meléndez1, Jennifer L McLarty, Scott P Levick, Yan Du, Joseph S Janicki, Gregory L Brower.   

Abstract

Although there is a correlation between hypertension and levels of interleukin (IL) 6, the exact role this cytokine plays in myocardial remodeling is unknown. This is complicated by the variable tissue and circulating levels of IL-6 reported in numerous experimental models of hypertension. Accordingly, we explored the hypothesis that elevated levels of IL-6 mediate adverse myocardial remodeling. To this end, adult male Sprague-Dawley rats were infused with IL-6 (2.5 microg . kg(-1) . h(-1), IP) for 7 days via osmotic minipump and compared with vehicle-infused, aged-matched controls. Left ventricular function was evaluated using a blood-perfused isolated heart preparation. Myocardial interstitial collagen volume fraction and isolated cardiomyocyte size were also assessed. Isolated adult cardiac fibroblast experiments were performed to determine the importance of the soluble IL-6 receptor in mediating cardiac fibrosis. IL-6 infusions in vivo resulted in concentric left ventricular hypertrophy, increased ventricular stiffness, a marked increase in collagen volume fraction (6.2% versus 1.7%; P<0.001), and proportional increases in cardiomyocyte width and length, all independent of blood pressure. The soluble IL-6 receptor in combination with IL-6 was found to be essential to producing increased collagen concentration by isolated cardiac fibroblasts and also played a role in mediating a phenotypic conversion to myofibroblasts. These novel observations demonstrate that IL-6 induces a myocardial phenotype almost identical to that of the hypertensive heart, identifying IL-6 as potentially important in this remodeling process.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20606113      PMCID: PMC2921860          DOI: 10.1161/HYPERTENSIONAHA.109.148635

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  41 in total

1.  An emerging role for inflammatory cytokines in hypertension.

Authors:  Joey P Granger
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-03       Impact factor: 4.733

2.  New method to evaluate myocyte remodeling from formalin-fixed biopsy and autopsy material.

Authors:  A M Gerdes; T Onodera; T Tamura; S Said; T J Bohlmeyer; W T Abraham; M R Bristow
Journal:  J Card Fail       Date:  1998-12       Impact factor: 5.712

3.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure.

Authors:  T Tsutamoto; T Hisanaga; A Wada; K Maeda; M Ohnishi; D Fukai; N Mabuchi; M Sawaki; M Kinoshita
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

4.  Cardiotrophin-1 increases angiotensinogen mRNA in rat cardiac myocytes through STAT3 : an autocrine loop for hypertrophy.

Authors:  J Fukuzawa; G W Booz; R A Hunt; N Shimizu; V Karoor; K M Baker; D E Dostal
Journal:  Hypertension       Date:  2000-06       Impact factor: 10.190

5.  Angiotensin II hypertension is attenuated in interleukin-6 knockout mice.

Authors:  Dexter L Lee; Lashon C Sturgis; Hicham Labazi; James B Osborne; Cassandra Fleming; Jennifer S Pollock; Marlina Manhiani; John D Imig; Michael W Brands
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-11-11       Impact factor: 4.733

6.  Differential integrin expression by cardiac fibroblasts from hypertensive and exercise-trained rat hearts.

Authors:  Maria Lonnett Burgess; Louis Terracio; Toshiro Hirozane; Thomas K Borg
Journal:  Cardiovasc Pathol       Date:  2002 Mar-Apr       Impact factor: 2.185

Review 7.  Interleukin-6 biology is coordinated by membrane bound and soluble receptors.

Authors:  Stefan Rose-John
Journal:  Acta Biochim Pol       Date:  2003       Impact factor: 2.149

8.  A role for cardiac mast cells in the pathogenesis of hypertensive heart disease.

Authors:  Naotaka Shiota; Jaana Rysä; Petri T Kovanen; Heikki Ruskoaho; Jorma O Kokkonen; Ken A Lindstedt
Journal:  J Hypertens       Date:  2003-10       Impact factor: 4.844

9.  Fasudil attenuates myocardial fibrosis in association with inhibition of monocyte/macrophage infiltration in the heart of DOCA/salt hypertensive rats.

Authors:  Kazuhiro Ishimaru; Hitoshi Ueno; Satoshi Kagitani; Daisuke Takabayashi; Masanobu Takata; Hiroshi Inoue
Journal:  J Cardiovasc Pharmacol       Date:  2007-08       Impact factor: 3.105

10.  Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients.

Authors:  Espen Haugen; Li-Ming Gan; Azra Isic; Tomas Skommevik; Michael Fu
Journal:  Exp Clin Cardiol       Date:  2008
View more
  170 in total

1.  Fasudil, a Rho-kinase inhibitor, protects against excessive endurance exercise training-induced cardiac hypertrophy, apoptosis and fibrosis in rats.

Authors:  Tsung-Jung Ho; Chi-Chang Huang; Chih-Yang Huang; Wan-Teng Lin
Journal:  Eur J Appl Physiol       Date:  2011-12-09       Impact factor: 3.078

2.  Moxonidine improves cardiac structure and performance in SHR through inhibition of cytokines, p38 MAPK and Akt.

Authors:  H Aceros; G Farah; L Cobos-Puc; A M Stabile; N Noiseux; S Mukaddam-Daher
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

3.  Differential Effects of Prevention and Reversal Treatment with Lisinopril on Left Ventricular Remodelling in a Rat Model of Heart Failure.

Authors:  Gregory L Brower; Scott P Levick; Joseph S Janicki
Journal:  Heart Lung Circ       Date:  2015-03-13       Impact factor: 2.975

Review 4.  Role of interleukin-6 in regulation of immune responses to remodeling after myocardial infarction.

Authors:  Mingyuan Huang; Du Yang; Meixiang Xiang; Jianan Wang
Journal:  Heart Fail Rev       Date:  2015-01       Impact factor: 4.214

5.  Methylsulfonylmethane decreases inflammatory response to tumor necrosis factor-α in cardiac cells.

Authors:  Lindsey E Miller
Journal:  Am J Cardiovasc Dis       Date:  2018-06-15

6.  A-kinase-anchoring protein-Lbc anchors IκB kinase β to support interleukin-6-mediated cardiomyocyte hypertrophy.

Authors:  Cosmo Damiano del Vescovo; Susanna Cotecchia; Dario Diviani
Journal:  Mol Cell Biol       Date:  2012-10-22       Impact factor: 4.272

7.  The Cardiomyocyte as a Source of Cytokines in Cardiac Injury.

Authors:  Toshinori Aoyagi; Takashi Matsui
Journal:  J Cell Sci Ther       Date:  2011-12-01

8.  Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling.

Authors:  Katrin Sobel; Katalin Menyhart; Nina Killer; Bérengère Renault; Yasmina Bauer; Rolf Studer; Beat Steiner; Martin H Bolli; Oliver Nayler; John Gatfield
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

9.  Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease.

Authors:  Stephen J Horgan; Chris J Watson; Nadia Glezeva; Pat Collier; Roisin Neary; Isaac J Tea; Niamh Corrigan; Mark Ledwidge; Ken McDonald; John A Baugh
Journal:  J Cardiovasc Transl Res       Date:  2015-11-17       Impact factor: 4.132

10.  The ubiquitous interleukin-6: a time for reappraisal.

Authors:  Enrique Z Fisman; Alexander Tenenbaum
Journal:  Cardiovasc Diabetol       Date:  2010-10-11       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.